Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

Carlo Albera, Ulrich Costabel, Elizabeth A. Fagan, Marilyn K Glassberg Csete, Eduard Gorina, Lisa Lancaster, David J. Lederer, Steven D. Nathan, Dominique Spirig, Jeff J. Swigris

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease progression and the effects of pirfenidone in patients stratified by more preserved versus less preserved baseline lung function status using forced vital capacity (FVC) or GAP (gender, age and physiology) index stage. Efficacy outcomes, i.e. FVC, 6-min walking distance (6MWD) and dyspnoea (University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)), were analysed at 12 months in patients randomised to pirfenidone 2403 mgday?1 or placebo in the pooled phase 3 CAPACITY/ASCEND population (n=1247), with subgroups stratified by baseline FVC ?80% versus <80% or GAP stage I versus II-III. Treatment-by-subgroup interaction was tested based on a rank ANCOVA model; factors in the model included study, region, treatment, subgroup and treatment-by-subgroup interaction term. Patients with both more preserved (FVC ?80% or GAP stage I) and less preserved (FVC <80% or GAP stage II-III) lung function at baseline demonstrated clinically significant disease progression at 12 months in terms of categorical decline in FVC, 6MWD and UCSD SOBQ. The magnitude of pirfenidone treatment effect was comparable between subgroups, regardless of whether lung function was classified using FVC or GAP index stage. These findings support the initiation of treatment with pirfenidone, irrespective of stage of baseline lung function in this patient population.

Original languageEnglish (US)
Pages (from-to)843-851
Number of pages9
JournalEuropean Respiratory Journal
Volume48
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Idiopathic Pulmonary Fibrosis
Vital Capacity
Lung
Dyspnea
Walking
Disease Progression
Therapeutics
pirfenidone
Population
Lung Diseases
Placebos

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. / Albera, Carlo; Costabel, Ulrich; Fagan, Elizabeth A.; Glassberg Csete, Marilyn K; Gorina, Eduard; Lancaster, Lisa; Lederer, David J.; Nathan, Steven D.; Spirig, Dominique; Swigris, Jeff J.

In: European Respiratory Journal, Vol. 48, No. 3, 01.09.2016, p. 843-851.

Research output: Contribution to journalArticle

Albera, C, Costabel, U, Fagan, EA, Glassberg Csete, MK, Gorina, E, Lancaster, L, Lederer, DJ, Nathan, SD, Spirig, D & Swigris, JJ 2016, 'Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function', European Respiratory Journal, vol. 48, no. 3, pp. 843-851. https://doi.org/10.1183/13993003.01966-2015
Albera, Carlo ; Costabel, Ulrich ; Fagan, Elizabeth A. ; Glassberg Csete, Marilyn K ; Gorina, Eduard ; Lancaster, Lisa ; Lederer, David J. ; Nathan, Steven D. ; Spirig, Dominique ; Swigris, Jeff J. / Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. In: European Respiratory Journal. 2016 ; Vol. 48, No. 3. pp. 843-851.
@article{30fe5735f3d84510ae98eba48ffe0a95,
title = "Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function",
abstract = "This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease progression and the effects of pirfenidone in patients stratified by more preserved versus less preserved baseline lung function status using forced vital capacity (FVC) or GAP (gender, age and physiology) index stage. Efficacy outcomes, i.e. FVC, 6-min walking distance (6MWD) and dyspnoea (University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)), were analysed at 12 months in patients randomised to pirfenidone 2403 mgday?1 or placebo in the pooled phase 3 CAPACITY/ASCEND population (n=1247), with subgroups stratified by baseline FVC ?80{\%} versus <80{\%} or GAP stage I versus II-III. Treatment-by-subgroup interaction was tested based on a rank ANCOVA model; factors in the model included study, region, treatment, subgroup and treatment-by-subgroup interaction term. Patients with both more preserved (FVC ?80{\%} or GAP stage I) and less preserved (FVC <80{\%} or GAP stage II-III) lung function at baseline demonstrated clinically significant disease progression at 12 months in terms of categorical decline in FVC, 6MWD and UCSD SOBQ. The magnitude of pirfenidone treatment effect was comparable between subgroups, regardless of whether lung function was classified using FVC or GAP index stage. These findings support the initiation of treatment with pirfenidone, irrespective of stage of baseline lung function in this patient population.",
author = "Carlo Albera and Ulrich Costabel and Fagan, {Elizabeth A.} and {Glassberg Csete}, {Marilyn K} and Eduard Gorina and Lisa Lancaster and Lederer, {David J.} and Nathan, {Steven D.} and Dominique Spirig and Swigris, {Jeff J.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1183/13993003.01966-2015",
language = "English (US)",
volume = "48",
pages = "843--851",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

AU - Albera, Carlo

AU - Costabel, Ulrich

AU - Fagan, Elizabeth A.

AU - Glassberg Csete, Marilyn K

AU - Gorina, Eduard

AU - Lancaster, Lisa

AU - Lederer, David J.

AU - Nathan, Steven D.

AU - Spirig, Dominique

AU - Swigris, Jeff J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease progression and the effects of pirfenidone in patients stratified by more preserved versus less preserved baseline lung function status using forced vital capacity (FVC) or GAP (gender, age and physiology) index stage. Efficacy outcomes, i.e. FVC, 6-min walking distance (6MWD) and dyspnoea (University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)), were analysed at 12 months in patients randomised to pirfenidone 2403 mgday?1 or placebo in the pooled phase 3 CAPACITY/ASCEND population (n=1247), with subgroups stratified by baseline FVC ?80% versus <80% or GAP stage I versus II-III. Treatment-by-subgroup interaction was tested based on a rank ANCOVA model; factors in the model included study, region, treatment, subgroup and treatment-by-subgroup interaction term. Patients with both more preserved (FVC ?80% or GAP stage I) and less preserved (FVC <80% or GAP stage II-III) lung function at baseline demonstrated clinically significant disease progression at 12 months in terms of categorical decline in FVC, 6MWD and UCSD SOBQ. The magnitude of pirfenidone treatment effect was comparable between subgroups, regardless of whether lung function was classified using FVC or GAP index stage. These findings support the initiation of treatment with pirfenidone, irrespective of stage of baseline lung function in this patient population.

AB - This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease progression and the effects of pirfenidone in patients stratified by more preserved versus less preserved baseline lung function status using forced vital capacity (FVC) or GAP (gender, age and physiology) index stage. Efficacy outcomes, i.e. FVC, 6-min walking distance (6MWD) and dyspnoea (University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)), were analysed at 12 months in patients randomised to pirfenidone 2403 mgday?1 or placebo in the pooled phase 3 CAPACITY/ASCEND population (n=1247), with subgroups stratified by baseline FVC ?80% versus <80% or GAP stage I versus II-III. Treatment-by-subgroup interaction was tested based on a rank ANCOVA model; factors in the model included study, region, treatment, subgroup and treatment-by-subgroup interaction term. Patients with both more preserved (FVC ?80% or GAP stage I) and less preserved (FVC <80% or GAP stage II-III) lung function at baseline demonstrated clinically significant disease progression at 12 months in terms of categorical decline in FVC, 6MWD and UCSD SOBQ. The magnitude of pirfenidone treatment effect was comparable between subgroups, regardless of whether lung function was classified using FVC or GAP index stage. These findings support the initiation of treatment with pirfenidone, irrespective of stage of baseline lung function in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84986182380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986182380&partnerID=8YFLogxK

U2 - 10.1183/13993003.01966-2015

DO - 10.1183/13993003.01966-2015

M3 - Article

C2 - 27471208

AN - SCOPUS:84986182380

VL - 48

SP - 843

EP - 851

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 3

ER -